Ascendis Pharma A/S EBITDA 2011-2026 | ASND

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Ascendis Pharma A/S

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-452 M	-331 M	-227 M	-155 M	-112 M	-72.2 M	-41.3 M	-11.5 M	5.68 M	1.94 M	-

All numbers in EUR currency

Indicator range from annual reports

Maximum	Minimum	Average
5.68 M	-452 M	-139 M

Quarterly EBITDA Ascendis Pharma A/S

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-128 M	-	-96.9 M	-118 M	-125 M	-	-78.8 M	-82.9 M	-73.2 M	-	-54 M	-51.6 M	-56.3 M	-	-38.3 M	-45.4 M	-35.2 M	-	-31.5 M	-24.7 M	-23.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in EUR currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-23.6 M	-128 M	-66.4 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Alector ALEC	-150 M	$ 2.11	-13.17 %	$ 217 M	USA
Acer Therapeutics ACER	-24.5 M	-	2.71 %	$ 14 M	USA
Axsome Therapeutics AXSM	-166 M	$ 163.89	-	$ 8.15 B	USA
BridgeBio Pharma BBIO	-518 M	$ 64.28	-3.31 %	$ 12.3 B	USA
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
BioCardia BCDA	-11.6 M	$ 1.37	5.81 %	$ 29 M	USA
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
AgeX Therapeutics AGE	-9.76 M	-	-10.17 %	$ 12.2 K	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
BioLineRx Ltd. BLRX	-24.8 M	$ 2.82	-0.35 %	$ 908 M	Israel
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
BioMarin Pharmaceutical BMRN	489 M	$ 59.8	-3.13 %	$ 11.5 B	USA
Bristol-Myers Squibb Company BMY	4.01 B	$ 62.08	-0.46 %	$ 126 B	USA
Benitec Biopharma BNTC	-9.77 M	$ 10.93	0.23 %	$ 450 M	USA
BioNTech SE BNTX	15.3 B	$ 109.33	-0.82 %	$ 27.2 B	Germany
Black Diamond Therapeutics BDTX	-78.4 M	$ 2.38	-3.44 %	$ 131 M	USA
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
BioXcel Therapeutics BTAI	-66.9 M	$ 1.63	-2.4 %	$ 4.13 M	USA
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
Burford Capital Limited BUR	242 M	$ 8.65	2.49 %	$ 1.39 B	Britain
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
AIkido Pharma AIKI	-11.4 M	-	1.93 %	$ 17.4 M	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
BeyondSpring BYSI	-66.2 M	$ 1.34	-0.87 %	$ 54 M	USA
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
Allena Pharmaceuticals ALNA	-47.3 M	-	3.16 %	$ 1.9 M	USA
Cabaletta Bio CABA	-73.2 M	$ 3.34	0.61 %	$ 3.9 M	USA
Aileron Therapeutics ALRN	-65 M	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	-200 M	-	4.14 %	$ 49.1 M	USA
Can-Fite BioPharma Ltd. CANF	-10.1 M	$ 4.88	2.74 %	$ 10.6 B	Israel
Alpine Immune Sciences ALPN	-57.6 M	-	-	$ 2.17 B	USA
Capricor Therapeutics CAPR	-23 M	$ 27.28	-2.32 %	$ 731 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Ampio Pharmaceuticals AMPE	122 K	-	-11.43 %	$ 502 K	USA
Catalyst Biosciences CBIO	-66.2 M	$ 11.67	-3.47 %	$ 768 M	USA
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
Aravive ARAV	-70 M	-	-13.39 %	$ 1.45 M	USA
C4 Therapeutics CCCC	-113 M	$ 3.06	13.3 %	$ 254 M	USA
Aptose Biosciences APTO	32 K	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	-62.4 M	-	-39.0 %	$ 4.57 M	USA
Athira Pharma ATHA	-99.9 M	-	-	$ 269 M	USA
Codexis CDXS	-53.6 M	$ 0.99	-2.04 %	$ 72.7 M	USA
Aridis Pharmaceuticals ARDS	-29.5 M	-	17.91 %	$ 11.1 M	USA